with report generated you stage pleased commercial good us launch YCANTH being morning, joining quarter our pipeline. the we business, progress to and from of Thank you, make to continue our XXXX including for data our for across earnings and exciting and the second everyone, thank call.
I'm that Kevin, development
Starting with YCANTH.
the reflects which onetime partner $X.X our order. as addition Cencora for in product and specialty growth quarter, expansion of YCANTH revenue we a with million, the impact net well recorded second a as footprint of stock in as For of of related the demand the distribution distribution
us allows target drive and further through is IPN's and IPN, customer which bill to support Cencora provide to through dermatologists account GPO buy intended their growth additional membership.
added also YCANTH's we on pull-through for a Vizient we see year. as second the We've a the half GPO in believe impact hospitals, of demand will positive and
We driving And on we believe the that addressed back year, focus in half operational adoption. hurdles. must and share we've market many of big the capturing
the published an at X, schedule CMS. treat We July Part for to a average plus focus on X, permanent price selling On to the simplifying process patients. physicians X%. April listing YCANTH B from on continue YCANTH CMS received And J-Code reimbursement
physicians allowables, amount published their electronically to further pleased report created own now YCANTH insurers for establish their at a This health of commercial that to will represents today, time is visible visibility coverage of maximum pay of companies lives with diagnosis. XX% which plan commercial covering service. for to the insurance as approximately I'm covered have allowables, the formally which care
confidence in accounts. additional this and buy that payer drive established believe bill and We for treatment should same-day coverage
commercial pharmacy will buy YCANTH's build, channels. to our talk for efforts to we driving proposition In specific adoption value we and both in to momentum additional the strategy addition commercialization a continue more across of specialty to look Joe build and about In growth promote YCANTH. as in maximize customers moment,
in sale States. products compounded in Laboratories containing compounded removing the In cantharidin of by will to we United a continue cantharidin make the progress announced products July, that U.S. Dormer the litigation settlement We in with discontinue Dormer
a safe, for supplier the the settlement treatment a win Dormer FDA-approved access with for and market, patients major U.S. As the effective marks to therapy largest products into cantharidin-containing of who of the non-FDA-approved molluscum. seek
While from time dating. marketplace YCANTH, cantharidin removing we impact compounded have positive demand a a for take will X-month sentiment as will have compounded the on this expect products typically
but for work on its will We, Dormer's recognize take customer inventory therefore, offices. some to time sold we conversion, previously way it remain focused through
While our for for just we product. developing molluscum, the unique beginning think treatment the main of remains opportunity that's focus market this innovative the for YCANTH and
treatment common one in in is opportunity all the The next And of the for largest of no million unmet patients approximately U.S. major therapies, the with warts. alone YCANTH XX warts the for represents of of prevalence and needs dermatology. common FDA-approved
warts continue We program. common to advancing our in make progress important
both agreement existing with trial licensing During pivotal that jointly the Phase global a amended we the common conduct for warts. cost so in will YCANTH of Pharmaceutical Torii companies quarter, our split and III
Torii Verrica's to for future cost milestones as Japan. common of on and Verrica payment YCANTH Torii's warts an to obligations will fund of the molluscum and in portion based regulatory offset contagiosum sales
dosed In addition, III trial. upon $X Torii the will in first payment the patient in Verrica Japan a make milestone million of Phase to
on should amendment and this funding have and time position. both market standpoint benefit a minimal Importantly, cash new near-term to from expected our impact parties to the is structure cost
to Initiation FDA design Japan's U.S. the trial. III the global and and from III of Phase Phase Pharmaceuticals a Medical of Device on proposed study feedback remains subject Agency the
QX the FDA anticipate first And half the III feedback line time initiating in year. receive XXXX. on from Phase the We current in this trial based expect the of and our of we estimates, to PMDA
and our If and high we for call YCANTH. a YCANTH overlap of the of point warts, molluscum anticipate promotion with is successfully synergies degree developed, of common marketing current treatment commercialized approved
for candidate the way that has treatment the our I'd like for cells. is a destroy system first-in-class potential cell which cancer peptide exciting to oncolytic to delivery to engineered more the data developed being basal and patient's carcinoma. Now provide review By pipeline of this of the is background, VP-XXX briefly stimulate immune been targeted VP-XXX, announced we lead morning
including neoadjuvant as for therapy or developing are alternative a including as that cell can potential a We chemotherapeutic carcinomas, nonsurgical as VP-XXX [indiscernible] serve cell. basal surgery, to basal surgery, a advanced
alone.
The that an of cell expect basal designed study we United in Phase II type tolerability, proof-of-concept X.X efficacy Preliminary the to cell the complete trial globally, safety XX lesions open-label million As year regimen and show the carcinoma. for opportunity clearance rate and with each is commercial the of is VP-XXX common basal States diagnoses carcinoma histologic biopsy-confirmed assess in with approximately sizable carcinoma. the data basal treated out treatment efficacy most in on XX% that of dose cell XX based approximately resulted of cancer VP-XXX
In who carcinoma, approximately addition, the residual tumors tumor reduction patients in had those residual XX% size. showed of
reduction treated. all Taken across in size together, approximately this XX% lesions tumor overall represents
entirely strong treatment confirmed of in eliminate use basal a treatment if results, which significantly the the surgery. argument [indiscernible] make for VP-XXX additional including either other of associated and will first-line of therapy the as in These regimens, pivotal need for excision size and reduce the advanced local a the with carcinoma, or treatment surgical the study, cell burden
events site to adverse adverse most Phase moderate treatment-related II with being pain common in as most and expected serious No adverse reported treatment-related classified as injection study, event. were the the mild events were
systemic instead for Based an effects. on potential the of these to from use believe significant prior surgery which or positive has treatment efficacy to first-line we for and safety become VP-XXX cell side therapies, oral carcinoma have basal option trial, Phase important data significant II
and with II physician results more to from pleased provide near future hold very detail VP-XXX discuss Phase obviously study to intend the data, event additional case. the these clinical the a are insight in use We and we in KOL into
commercial I'll to to turn our Joe over now call the review progress. Joe?
